Increasingly Lucrative Market Fueled by Constrained Payer Environment and Patent Expiries for Best-Selling Biologics
A constrained payer environment and patent expiration of a number of best-selling biologics such as Humira (adalimumab), Rituxan/MabThera (rituximab) and Herceptin (trastuzumab) represent key drivers of global biosimilar market growth.
Government support for biosimilars is increasing in key mature and emerging markets, given the cost-saving opportunities that these products represent for national healthcare budgets. Consequently, biosimilars are expected to be the leading growth drivers of the pharmaceutical industry in 2019.
There are 492 biosimilars in active development across a range of therapy areas, a large proportion of which are in late-stage development. Biosimilars in development for oncology and immunology indications are particularly prominent among the pipeline.
Key Questions Answered:
- What are the key drivers and barriers to biosimilar market growth?
- How does legislation regarding biosimilar interchangeability differ among key geographical markets?
- How will legal or political changes in the landscape affect the biosimilar market?
Report Format: electronic pdf